# Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

> **NCT04564833** · PHASE2 · COMPLETED · sponsor: **Renibus Therapeutics, Inc.** · enrollment: 152 (actual)

## Conditions studied

- AKI

## Interventions

- **DRUG:** Low Dose RBT-1
- **DRUG:** High Dose RBT-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04564833
- **Lead sponsor:** Renibus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-04
- **Primary completion:** 2022-11-09
- **Final completion:** 2023-02-03
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564833, "Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04564833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*